UNSPSC 51181614: Carbimazole

This classification denotes an antithyroid agent with the molecular formula C7H10N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8KQ660G60G, chemically known as 4-imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester but generally known as carbimazole, which bears US NIH Compound Identifier 31072. European Medicines Agency schedules Carbimazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06127MIG.

UNSPSC 51181614 Carbimazole is a Commodity code that covers the procurement of carbimazole, an antithyroid medication used to treat hyperthyroidism and related thyroid conditions. State and local governments purchase carbimazole primarily through their health departments, correctional facilities, public health clinics, and institutional healthcare systems that serve incarcerated populations, indigent patients, and other publicly funded beneficiaries. The medication is typically sourced as a finished pharmaceutical product in tablet or capsule form and procured either as a one-time purchase or through standing supply agreements with pharmaceutical distributors or manufacturers.

The source provided contains no recent state or local contract opportunities tagged to this code. Without posted RFPs, RFQs, IFBs, or ITBs in the available record, the geographic distribution of carbimazole procurement activity and the current roster of active issuing bodies cannot be characterized. Organizations seeking to pursue this category should monitor procurement portals in states with large correctional or public health systems — particularly those with centralized pharmaceutical purchasing through state health departments or cooperative purchasing agreements — but should not expect frequent or predictable solicitation patterns, as pharmaceutical procurement often operates on multi-year contracts with infrequent rebids or is fulfilled through standing-price agreements with existing vendors rather than through open-market notices.